JUNE Medical Launches Galaxy II™ LUX and Partnership with Vivo Surgical

December 14, 2020

JUNE Medical has announced the launch of the Galaxy II™ LUX – the worlds’ first self-retaining ring retractor with light.

JUNE Medical notes the Galaxy II LUX combines the award-winning Galaxy II retractor with Vivo Surgical’s KLARO™ in vivo LED device, which can be mounted on the retractor via a purpose-designed clip.

This unique partnership provides surgeons with a revolutionary solution, giving them better access and a clearer view of the surgical site, and eliminating the disadvantages of using overhead lighting or personal head torches.

JUNE Medical notes the lightweight, self-retaining Galaxy II retractor features unique cam locks that allow single-handed adjustment on the frame, and there are multiple frames and hooks to suit a range of procedures. The KLARO lighting tip then offers the highest surgical light intensity on the market, with four settings to match the needs of different operations, while maintaining a safe operating temperature of below 38 °C. With a650 mm long cable, compact 4.6 mm diameter and flexible structure, the light can be effortlessly positioned during surgery to offer up to ~340° of illumination inside deep and narrow wounds.

The Galaxy II LUX is ideal for use in a variety of procedures, including ENT, colorectal, orthopedic, gynecological and other open surgeries. Angela Spang, CEO of JUNE Medical commented: “We are thrilled to be working with Vivo Surgical to offer this gamechanger. This kit helps to overcome a number of pain points, ensuring uniform site illumination from within an open surgical cavity, reducing the need for light repositioning and eliminating the risk of patient infection from contaminated light handles, as well as improving ergonomics for surgeons. We’re also excited about the opportunities this kit will bring for our charity work in countries where surgical lighting is sometimes a smartphone torch!”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version